Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 10/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801584 | 1.00 | HTT (0.46) | HTTGHSRPTPN11MEN1KMT2A | |
| SCHEMBL14163169 | 0.85 | GHSR (0.41) | HTTGHSRPTPN11MAPT | |
| SCHEMBL4933532 | 0.85 | GHSR (0.54) | HTTGHSRPTPN11LMNAMAPT | |
| SCHEMBL4933529 | 0.85 | GHSR (0.54) | HTTGHSRPTPN11LMNAMAPT | |
| SCHEMBL4216169 | 0.81 | HTT (0.46) | HTTGHSRPTPN11LCKBCL2A1 | |
| SCHEMBL4802118 | 0.81 | GHSR (0.47) | GHSR | |
| SCHEMBL4216171 | 0.81 | HTT (0.46) | HTTGHSRPTPN11LCKBCL2A1 | |
| SCHEMBL4802129 | 0.81 | GHSR (0.47) | GHSR | |
| Hydrochloric Acid SCHEMBL4219984 | 0.79 | HTT (0.45) | HTTGHSRPTPN11KMT2ALCK | |
| Hydrochloric Acid SCHEMBL4219981 | 0.79 | HTT (0.45) | HTTGHSRPTPN11KMT2ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
| CN-101031564-A | Piperazine derivatives for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2007-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | HTT 1562/4885GHSR 1/4885PTPN11 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.